Alkem Laboratories Limited — PPTs, 07-02-2025: Investor Presentation

Alkem Laboratories reported its Q3 and 9MFY25 results showing modest growth in a challenging market. Total revenue from operations for Q3 stood at ₹33,743 million, a 1.5% year-over-year increase, driven by 5.9% growth in domestic sales (₹23,649 million). However, international sales faced a decline, dropping 6.2% to ₹9,605 million. EBITDA rose by 7.3% to ₹7,594 million, marking an improved margin of 22.5% compared to 21.3% in the prior year. The company posted a net profit of ₹6,258 million, up 5.2% YoY, reflecting positive operational efficiency initiatives.

For the nine-month period, revenue reached ₹98,208 million, a 0.9% increase, with domestic sales rising 6.0% and international sales decreasing by 7.7%. During this timeframe, EBITDA surged 15.0% to ₹21,209 million, contributing to a significant rise in net profit at ₹18,596 million, a notable growth of 23.8% compared to last year. These results affirm Alkem's resilience and ability to enhance profitability despite external challenges, signaling a positive outlook for strategic growth going forward. Investors should watch closely as the company continues to focus on high-margin segments and improving market penetration.